scispace - formally typeset
J

John F. Forbes

Researcher at University of Limerick

Publications -  373
Citations -  51254

John F. Forbes is an academic researcher from University of Limerick. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 88, co-authored 368 publications receiving 46433 citations. Previous affiliations of John F. Forbes include University of Newcastle & University of Melbourne.

Papers
More filters
Journal ArticleDOI

Clinical trial of prophylaxis of wound sepsis in elective colorectal surgery: Cephamandole with tinidazole versus tinidazole alone

TL;DR: There was a significant reduction in the mean wound infection rate in the combination chemotherapy group (P = 0.05, Fisher's exact test) when patients of the two surgeons who contributed two‐thirds of the patients in the trial were excluded from analysis.
Journal ArticleDOI

Association Between Walking Pace and Stroke Incidence: Findings From the UK Biobank Prospective Cohort Study.

TL;DR: Slow walking pace was associated with a higher risk of stroke among participants over 64 years of age in this population-based cohort study, and the addition of the measurement of self-reported walking pace to primary care or public health clinical consultations may be a useful screening tool for stroke risk.
Proceedings ArticleDOI

Optimal control of a time-varying catalytic fixed bed reactor with catalyst deactivation

TL;DR: The paper deals with the linear-quadratic control problem for a time-varying partial differential equation model of a catalytic fixed-bed reactor, and an optimal LQ-feedback is computed via the solution of a matrix Riccatipartial differential equation.
Journal ArticleDOI

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies

TL;DR: In this article, the authors investigated the association between body mass index (BMI) and breast cancer risk in women at increased risk of breast cancer receiving tamoxifen or anastrozole compared with placebo using data from the International Breast Cancer Intervention Studies (IBIS-I) and IBIS-II).